IGM Biosciences, Inc.
Anti-PD-L1 antibodies
Last updated:
Abstract:
Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.
Status:
Grant
Type:
Utility
Filling date:
9 May 2017
Issue date:
23 Mar 2021